Ubrelvy Shortage Update: What Patients Need to Know in 2026

If you've been unable to fill your Ubrelvy prescription recently, you're probably wondering: is there a shortage? It's a fair question. When pharmacy after pharmacy says they don't have your medication or your insurance won't cover it, it certainly feels like a shortage. Here's the current picture for 2026 — and what you can do.

Is Ubrelvy Currently in Shortage?

No. As of 2026, Ubrelvy (ubrogepant) is not listed on the FDA's official Drug Shortages database. AbbVie, the manufacturer (originally Allergan), is producing and distributing the medication through normal channels. There is no manufacturing disruption, FDA warning, or official recall.

However — and this is important — "not in shortage" does not mean "easy to find." Ubrelvy faces serious functional access barriers that prevent many patients from filling their prescriptions reliably. These are driven by economics and insurance, not manufacturing problems.

Why Do Patients Still Have Trouble Finding Ubrelvy?

Several factors create real-world access problems for Ubrelvy patients in 2026:

No generic available. Ubrelvy is a brand-name-only drug. No generic version of ubrogepant exists, and one isn't expected until at least 2035. The wholesale list price is $1,139.09 per 30-day supply as of January 2026.

Insurance barriers. Most commercial insurance plans require prior authorization or step therapy before covering Ubrelvy. About 4 in 5 ACA plan enrollees must try another migraine medication first. Medicare Part D coverage varies by plan.

Inconsistent pharmacy stocking. Many chain pharmacies carry limited quantities or don't stock Ubrelvy routinely, particularly in smaller markets. The unit-dose packet format and high price make it a low-priority stock item for some locations.

PBM routing. Some pharmacy benefit managers route Ubrelvy to specific preferred or specialty pharmacies, meaning your usual pharmacy may not be authorized to fill it under your plan.

Has Ubrelvy Ever Been in a Formal Shortage?

No. Since its FDA approval in December 2019, Ubrelvy has not been placed on the FDA's Drug Shortages database. This is different from drugs like semaglutide (Ozempic/Wegovy) or ADHD medications that have experienced documented manufacturing shortages. Ubrelvy's access problems are structural — they relate to pricing and coverage — rather than supply chain disruptions.

What's the 2026 Availability Outlook for Ubrelvy?

The availability outlook for 2026 is stable from a manufacturing standpoint. AbbVie continues to produce and distribute Ubrelvy, and there are no regulatory or safety events affecting supply. The drug remains on the market with no discontinuation plans announced.

What may shift over time: insurance coverage decisions. Some plans have changed their formulary tier placement for Ubrelvy, and coverage decisions may differ at open enrollment each year. Patients should check their specific plan's formulary for 2026 and verify prior authorization requirements.

What Should Patients Do Right Now?

If you're struggling to access Ubrelvy, here are the most effective steps:

Find a pharmacy that has it in stock. Use medfinder to quickly locate pharmacies near you that carry Ubrelvy. medfinder calls pharmacies so you don't have to.

Get the Ubrelvy savings card. Commercially insured patients may pay as little as $0/month with the Ubrelvy Complete Savings Card (max $7,000/year savings). Register at ubrelvy.com/savings or call 1-844-577-6239.

Work on prior authorization. Ask your doctor to submit a PA for your insurance. While PA is pending, the savings card may provide bridge fills at no charge.

Check eligibility for myAbbVie Assist. If you're uninsured or underinsured with limited income, the myAbbVie Assist patient assistance program can provide up to 12 months of Ubrelvy at no cost to qualifying patients.

Consider alternatives. If cost or access remains a barrier, other gepants like Nurtec ODT or affordable generic triptans like sumatriptan may provide effective acute migraine relief while you work on getting Ubrelvy covered.

Bottom Line

Ubrelvy is not in a formal FDA shortage in 2026, and supply is not an issue at the manufacturer level. Access challenges are real but driven by cost and insurance, not supply disruption. Armed with the right savings program and the right pharmacy-finding tools, most patients can successfully fill their Ubrelvy prescription. See our guide on how to find Ubrelvy in stock near you for step-by-step instructions.